Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants.

Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX.

Vaccine. 2012 Dec 17;31(1):159-64. doi: 10.1016/j.vaccine.2012.10.069. Epub 2012 Oct 30.

2.

Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.

McCluskie MJ, Pryde DC, Gervais DP, Stead DR, Zhang N, Benoit M, Robertson K, Kim IJ, Tharmanathan T, Merson JR, Davis HL.

Int Immunopharmacol. 2013 May;16(1):50-6. doi: 10.1016/j.intimp.2013.03.021. Epub 2013 Apr 2.

PMID:
23562759
3.

Laser vaccine adjuvant for cutaneous immunization.

Chen X, Wu MX.

Expert Rev Vaccines. 2011 Oct;10(10):1397-403. doi: 10.1586/erv.11.112.

4.

Micro-fractional epidermal powder delivery for improved skin vaccination.

Chen X, Kositratna G, Zhou C, Manstein D, Wu MX.

J Control Release. 2014 Oct 28;192:310-6. doi: 10.1016/j.jconrel.2014.08.006. Epub 2014 Aug 15.

5.

Enhancing nicotine vaccine immunogenicity with liposomes.

Lockner JW, Ho SO, McCague KC, Chiang SM, Do TQ, Fujii G, Janda KD.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):975-8. doi: 10.1016/j.bmcl.2012.12.048. Epub 2012 Dec 27.

6.

A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle.

Hu Y, Zheng H, Huang W, Zhang C.

Hum Vaccin Immunother. 2014;10(1):64-72. doi: 10.4161/hv.26635. Epub 2013 Oct 7.

7.

Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy.

Cornish KE, Harris AC, LeSage MG, Keyler DE, Burroughs D, Earley C, Pentel PR.

Int Immunopharmacol. 2011 Nov;11(11):1809-15. doi: 10.1016/j.intimp.2011.07.009. Epub 2011 Jul 28.

8.

Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum.

de Villiers SH, Cornish KE, Troska AJ, Pravetoni M, Pentel PR.

Vaccine. 2013 Dec 16;31(52):6185-93. doi: 10.1016/j.vaccine.2013.10.051. Epub 2013 Oct 29.

9.

Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.

Zhao Z, Powers K, Hu Y, Raleigh M, Pentel P, Zhang C.

Biomaterials. 2017 Apr;123:107-117. doi: 10.1016/j.biomaterials.2017.01.038. Epub 2017 Jan 27.

PMID:
28167389
10.

Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions.

Cornish KE, de Villiers SH, Pravetoni M, Pentel PR.

PLoS One. 2013 Dec 2;8(12):e82557. doi: 10.1371/journal.pone.0082557. eCollection 2013.

11.

Probing the protective effects of a conformationally constrained nicotine vaccine.

Moreno AY, Azar MR, Koob GF, Janda KD.

Vaccine. 2012 Oct 19;30(47):6665-70. doi: 10.1016/j.vaccine.2012.08.064. Epub 2012 Sep 7.

PMID:
22963803
12.

New directions in nicotine vaccine design and use.

Pentel PR, LeSage MG.

Adv Pharmacol. 2014;69:553-80. doi: 10.1016/B978-0-12-420118-7.00014-7. Review.

13.

Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.

Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, Horwith G, Pentel PR.

Clin Pharmacol Ther. 2005 Nov;78(5):456-67. Erratum in: Clin Pharmacol Ther. 2006 Apr;79(4):396.

PMID:
16321612
14.

Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.

Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO.

Vaccine. 2000 Oct 15;19(4-5):530-7.

PMID:
11027818
15.
16.

Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats.

Roiko SA, Harris AC, Keyler DE, Lesage MG, Zhang Y, Pentel PR.

J Pharmacol Exp Ther. 2008 Jun;325(3):985-93. doi: 10.1124/jpet.107.135111. Epub 2008 Feb 27.

17.

A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy.

Zhao Z, Hu Y, Hoerle R, Devine M, Raleigh M, Pentel P, Zhang C.

Nanomedicine. 2017 Feb;13(2):443-454. doi: 10.1016/j.nano.2016.07.015. Epub 2016 Aug 9.

PMID:
27520729
18.

Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.

Liao HX, Cianciolo GJ, Staats HF, Scearce RM, Lapple DM, Stauffer SH, Thomasch JR, Pizzo SV, Montefiori DC, Hagen M, Eldridge J, Haynes BF.

Vaccine. 2002 May 22;20(17-18):2396-403.

PMID:
12009296
19.

A novel laser vaccine adjuvant increases the motility of antigen presenting cells.

Chen X, Kim P, Farinelli B, Doukas A, Yun SH, Gelfand JA, Anderson RR, Wu MX.

PLoS One. 2010 Oct 29;5(10):e13776. doi: 10.1371/journal.pone.0013776.

20.

Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.

Mazumder S, Maji M, Ali N.

PLoS Negl Trop Dis. 2011 Dec;5(12):e1429. doi: 10.1371/journal.pntd.0001429. Epub 2011 Dec 20.

Supplemental Content

Support Center